Table 3. The top mutations associated with phenotypic drug resistance.

	GENE	VARIANT	n	%
Rifampicin	rpoB	S450L	2,914	62.2
	rpoB	D435V	506	10.8
	rpoB	H445D	202	4.3
	rpoB	H445Y	147	3.1
	rpoB	D435Y	112	2.4
Isoniazid	katG	S315T	3,668	70.0
	fabG1	c-15t	829	15.8
	fabG1	g-17t	176	3.4
	fabG1	t-8c	154	2.9
	inhA	I194T	56	1.1
Ethambutol	embB	M306V	1,131	50.0
	embB	M306I	1,001	44.3
	embB	Q497R	449	19.9
	embB	G406A	164	7.2
	embB	G406D	105	4.6
Kanamycin	rrs	a1401g	660	58.9
	eis	c-14t	70	6.2
	eis	g-10a	53	4.7
Amikacin	rrs	a1401g	660	74.7
	rrs	g1484t	7	0.8
Levofloxacin	gyrA	D94G	783	36.5
	gyrA	A90V	487	22.7
	gyrA	D94N	157	7.3
	gyrA	D94A	133	6.2
	gyrA	S91P	92	4.3
Moxifloxacin	gyrA	D94G	783	45.4
	gyrA	A90V	487	28.2
	gyrA	D94N	157	9.1
	gyrA	D94A	133	7.7
	gyrA	D94Y	70	4.1
Ethionamide	fabG1	c-15t	829	48.0
	fabG1	L203L	124	7.2

Depicted is a survey of the resistance-associated mutations present in the data compendium [8,26]. “VARIANT”: nonsynonymous amino acid mutations are denoted by upper case letters, while nucleotide substitutions for noncoding sequences are denoted by lower case letters. Negative numbers denote substitutions in promoter regions; “GENE”: genic region of interest in which “Variant” can be found; “n”: number of phenotypically resistant isolates with “VARIANT”; “%”: percentage of total phenotypically resistant isolates with “VARIANT”.